Feedback / Questions
CB-5339 - Cleave Therap
https://www.prnewswire.com/news-releases/cleave-therapeutics-licenses-first-in-class-vcpp97-inhibitor-cb-5339-to-casi-pharmaceuticals-for-greater-china-region-301242012.html
Mar 8, 2021
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next